Valeant Pharmaceuticals International News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.10.08	Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Biovail Corporation (Businesswire)
13.08.08	Please kill this story. (Businesswire)
11.08.08	Valeant Pharmaceuticals Reports Second Quarter Financial Results (Businesswire)
14.05.08	Valeant gibt erfolgreichen Abschluss seiner Phase-III-Retigabin-Studien zur Validierung von neuem Wirkmechanismus in der Epilepsietherapie bekannt (Businesswire)
07.05.08	Valeant Pharmaceuticals Reports 2008 First Quarter Financial Results (Businesswire)
28.02.08	Valeant Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results (Businesswire)
20.12.07	Valeant Pharmaceuticals Sells Hep-C Drug Infergen(R) to Three Rivers Pharmaceuticals(R), LLC for $91 Million (Businesswire)
08.08.07	Biovail Reports Second-Quarter 2007 Financial Results (Businesswire)
02.08.07	Valeant Pharmaceuticals Reports Second Quarter 2007 Results (Businesswire)
10.07.07	Valeant Pharmaceuticals Selects Next-Generation Potassium-Channel Openers for Pre-Clinical Development (Businesswire)
26.04.07	Lonnie Ali Champions 'Fight For MORE' Campaign (PR Newswire)
23.01.07	Valeant Pharmaceuticals Files Restated Financial Statements and September 30, 2006 Form 10-Q (Businesswire)
22.12.06	Company Announces Acquisition of Research and Development Programs, Hiring of Senior Management Team and Name Change (PR Newswire)
12.12.06	Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study (Businesswire)
04.10.06	Intendis and Valeant Pharmaceuticals Sign Distribution Agreement for Finacea(R), a New Treatment in the UK for Rosacea (PR Newswire)
02.10.06	Valeant Pharmaceuticals Previews 24-Week Results of Direct Trial for Infergen(R) (Businesswire)
15.06.06	Valeant Pharmaceuticals Receives FDA Approval of Zelapar(R) for Patients with Parkinson's Disease; Zelapar Significantly Reduces ``Off'' Time through Unique Delivery Mechanism (Businesswire)
16.05.06	Valeant Pharmaceuticals Receives FDA Marketing Approval for Cannabinoid Cesamet(TM) (CII) (Businesswire)
03.04.06	Valeant Pharmaceuticals Announces Strategic Restructuring Plan (Businesswire)
09.03.06	Valeant Pharmaceuticals Signs Courteney Cox as Kinerase(R) Spokesperson (Businesswire)
28.02.06	Valeant Pharmaceuticals Reports Fourth Quarter and Full Year 2005 Results (Businesswire)
04.11.05	Valeant Pharmaceuticals Declares 2005 Third Quarter Dividend (Businesswire)
04.08.05	Valeant Pharmaceuticals Reports Second Quarter 2005 Results; Revenues Increase 20 Percent; Product Sales Advance 22 Percent (Businesswire)
06.05.05	Biovail Receives Approval Letter From FDA For Tramadol ODT; Oral Disin (Businesswire)
05.05.05	Valeant Pharmaceuticals Reports First Quarter 2005 Results; Product Sa (Businesswire)
18.04.05	Valeant Pharmaceuticals Presents Final Analyses of Viramidine Phase 2 (Businesswire)
30.03.05	Biovail Updates Status of NDA for Tramadol ER (Businesswire)
10.03.05	Biovail Reports Fourth Quarter, Year-End 2004 Financial Results (Businesswire)
22.02.05	Biovail Announces $27.6-Million Expansion to Steinbach, Manitoba Manuf (Businesswire)
02.02.05	Valeant Pharmaceuticals to Acquire Xcel Pharmaceuticals; Acquisition E (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Valeant Pharmaceuticals International Inc.

Aktien Top/Flop

Meistgelesene Nachrichten